Entera Bio Ltd. (ENTX)
| Market Cap | 531.33M +326.1% |
| Revenue (ttm) | n/a -76.8% |
| Net Income | -17.03M |
| EPS | -0.35 |
| Shares Out | 173.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,047 |
| Open | 3.190 |
| Previous Close | 3.200 |
| Day's Range | 2.990 - 3.290 |
| 52-Week Range | 0.910 - 4.200 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 9.75 (+219.15%) |
| Est. Earnings | Nov 13, 2026 |
About ENTX
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept... [Read more]
Financial Performance
In 2025, Entera Bio's revenue was $42,000, a decrease of -76.80% compared to the previous year's $181,000. Losses were -$11.44 million, 19.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ENTX stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 219.15% from the latest price.
News
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinica...
Entera Bio Proxy statement: Proxy filing
Entera Bio filed a proxy statement on October 14, 2026, providing details for shareholder voting and corporate governance matters.
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (oste...
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional present...
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biophar...
Guggenheim starts Entera with Buy on N-tab platform potential
Guggenheim last night initiated coverage of Entera Bio (ENTX) with a Buy rating and $11 price target The firm says its bullish view on Entera shares is driven by “enthusiasm”…
Entera Bio initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Entera Bio (ENTX) with a Buy rating and $11 price target
Entera Bio Proxy statement: Proxy filing
Entera Bio filed a proxy statement on September 23, 2026, providing details for shareholder voting and corporate governance matters.
Entera Bio initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Entera Bio (ENTX) with an Outperform rating and $10 price target
Entera Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entera Bio (ENTX) with an Overweight rating. Entera is positioned for significant upside with EB613, a potentially first-in-class oral osteoanabolic for osteopo...
Entera Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entera Bio (ENTX) with an Overweight rating.
Leerink bullish on Entera Bio, initiates with an Outperform
As previously reported, Leerink initiated coverage of Entera Bio (ENTX) with an Outperform rating and $9 price target representing about 200% upside to the current price of $3.03. The firm…
Entera Bio initiated with an Outperform at Leerink
Leerink initiated coverage of Entera Bio (ENTX) with an Outperform rating and $9 price target
Correction: Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief E...
Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief E...
Entera Bio files to sell 134.8M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 134.8M ordinary shares. The company is not selling any shares under…
Entera Bio Registration statement: Registration filing
Entera Bio filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Entera Bio names Riccardo Paolo Camisasca as chief medical officer
Entera Bio (ENTX) announced the appointment of Riccardo Paolo Camisasca as chief medical officer. Most recently, he served as global head of research and development at Sumitomo Pharma Switzerland. Pu...
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens ...
Entera Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference
EB613, an oral anabolic peptide for osteoporosis, is advancing to a streamlined phase III trial after FDA alignment, targeting a major treatment gap between antiresorptives and injectables. The candidate aims to improve bone health for a broader patient population and offers strong pharmacoeconomic potential.
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteop...
Entera Bio Quarterly report: Q2 2026
Entera Bio has published its Q2 2026 quarterly earnings report on August 7, 2026.
Entera Bio Earnings release: Q2 2026
Entera Bio released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase ...
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive...